Crosstalk of purinergic, endocannabinoid, stem cell, and immune signaling (CME track/practitioner registrants only)


Crosstalk of purinergic, endocannabinoid, stem cell, and immune signaling by CBDs, suramin, Scutellaria/baicalin, and quercetin will be discussed.

Learning objectives are to understand:

•    Purinergic and endocannabinoid signaling in the regulation of the immune system

•    Pathophysiology of purinergic signaling

•    Role of purinergic and endocannabinoid signaling in neural, hematopoietic, and mesenchymal stem cell maintenance and differentiation

•    Role of ectonucleotidases CD39 and CD73 in immunity and inflammation

•    Use of CD39 and CD73 companion diagnostics to monitor purinergic and endocannabinoid signaling


Judy A. Mikovits, PhD

Dr. Judy A. Mikovits earned her BA in chemistry with a specialization in biology from the University of Virginia in 1980 and her PhD in biochemistry and molecular biology from George Washington University in 1992. In her 35-year quest to understand and treat chronic diseases, she has co-authored seminal papers culminating at least a decade of research in each of four fields: immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development. In 2006, she became attracted to the plight of families with neuroimmune diseases including ME/CFS and autism. Dr. Mikovits has been primarily responsible for demonstrating the relationship between environmentally acquired immune dysfunction, chronic inflammation, and these diseases. Dr. Mikovits has coauthored more than 50 peer reviewed publications and book chapters and the book Plague: One Scientist’s Intrepid Search for the truth about Human Retroviruses and Chronic Fatigue Syndrome (ME/CFS), Autism and Other Diseases. Her pioneering work during her 20-year career at the National Cancer Institute includes the discovery of the modulation of DNA methylation machinery by human retro viral infection and the development of the concept of inflammatory cytokines and chemokine signatures of infection and disease, which was first published in 1999, when she directed the Laboratory of Antiviral Drug Mechanisms in developing therapeutics and diagnostics for HIV/AIDS and AIDS associated malignancies. These are therapies that are still standard of care twenty-five years later and credited with saving millions of deaths from HIV/AIDS